Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

Item
http://www.wikidata.org/entity/Q34093598
New therapeutics that modulate chemokine networks.New anti-HIV agents and targets.Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitorsChemokine receptor antagonists: part 2.Patented small molecules against psoriasis.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Targeting CCR5 for anti-HIV research.Identification of potential CCR5 inhibitors through pharmacophore-based virtual screening, molecular dynamics simulation and binding free energy analysis.Synthesis of (3) H, (2) H4 and (14) C-SCH 417690 (Vicriviroc).Bioisosteric Exchange of Csp3 -Chloro and Methyl Substituents: Synthesis and Initial Biological Studies of Atpenin A5 Analogues.Scalable Synthesis of Piperazines Enabled by Visible-Light Irradiation and Aluminum Organometallics.Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.
P2860

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

Item
http://www.wikidata.org/entity/Q34093598
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@ast
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@en
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@nl
type
label
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@ast
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@en
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@nl
prefLabel
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@ast
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@en
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Piperazine-based CCR5 antagoni ...... 350634), an orally bioavailabl
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P698